Jamie Harms, MD
Family Medicine · Queenstown, MDNPI 1780685073
Payments from drug & device makers
Across 135 payments — averaging $14.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$562
- AstraZeneca$180
- Amgen$163
- Boehringer Ingelheim$160
- AbbVie$93
- Merck$89
- plus $727 from 22 others
What the payments were for
- Food & beverage$1,967100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 46 | $562 |
| AstraZeneca | 13 | $180 |
| Amgen | 9 | $163 |
| Boehringer Ingelheim | 9 | $160 |
| AbbVie(2 entities) | 6 | $93 |
| Merck | 6 | $89 |
| Pfizer | 5 | $75 |
| Lilly USA, LLC | 4 | $70 |
| GSK | 4 | $66 |
| E.r. Squibb & Sons, L.L.C. | 4 | $61 |
| Amarin Pharma, Inc. | 2 | $47 |
| Abbott | 2 | $46 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $44 |
| Novartis | 2 | $44 |
| Amneal Pharmaceuticals LLC | 3 | $34 |
| Hikma Pharmaceuticals USA | 2 | $28 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Biohaven Pharmaceuticals, Inc. | 2 | $28 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Johnson & Johnson | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Eisai Inc. | 1 | $18 |
| Alkermes, Inc. | 1 | $16 |
| Philips North America LLC | 1 | $15 |
| IBSA Pharma Inc. | 1 | $13 |
| Otsuka America Pharmaceutical, Inc. | 1 | $13 |
| Medtronic | 1 | $12 |
| Dexcom, Inc. | 1 | $12 |
How this compares
$1,975 in reported general payments places this provider in the 75th percentile of 1,193 family medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atomoxetine Hcl | 12 | $1,627 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Queenstown
- Stephen OngOxon Hill$5.9M
- Stephan BartWoodstock$1.7M
- Karen DonaldsonBaltimore$899K
- Rajiv DuaColumbia$765K
- Greg TampusLutherville Timonium$735K
- Louis JacquesBaltimore$522K
- Stephanie MellerOxon Hill$518K
- Sharon ChungGlen Burnie$333K
- Michael ObiefuneBaltimore$291K
- Thomas LawrenceBerlin$254K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.